Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

Companion diagnostics (CDx) holds the promise of improving the predictability of the oncology drug development process and become an important tool for the oncologist in relation to the choice of treatment for the individual patient. A number of drug–diagnostic co-development programs have already b...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Dana, Jørgensen, Jan Trøst
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032883/
https://www.ncbi.nlm.nih.gov/pubmed/24904822
http://dx.doi.org/10.3389/fonc.2014.00105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032883/
https://www.ncbi.nlm.nih.gov/pubmed/24904822
http://dx.doi.org/10.3389/fonc.2014.00105

Ejemplares similares